Clinical trials: Infections, Respiratory
Influenza
Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older
The aim of this study is to determine the efficacy of Fluzone High Dose vaccine and that of Fluzone® vaccine in the elderly. Primary objective: To measure the efficacy of the vaccine, defined as the prevention of…
- Trial name
- NCT00976027
- Testing
- Trivalent inactivated influenza vaccine High Dose, Trivalent inactivated influenza vaccine
- Where
- 98 sites in United States, Puerto Rico
- Volunteers
- 9,172 people, healthy volunteers welcome
- Sponsor
- Sanofi
Allergic Rhinitis
Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine
Phase IIIb , longitudinal, multicenter, randomized, double-blind, to evaluate efficacy and safety of the fixed-dose combination of Desloratadine 5 mg / Betamethasone 0.25 mg versus Desloratadine 5 mg monotherapy as treatment for…
- Trial name
- DESCUBRA (NCT06916884)
- Testing
- Desloratadine / Betamethasone in fixed dose, Desloratadine
- Where
- Mexico
- Volunteers
- 70 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Influenza
Influenza Vaccine Challenge Study in Healthy Subjects
The purpose of this research is to study the safety, tolerability and effectiveness of the investigational influenza vaccine in healthy volunteers infected with an attenuated influenza A virus.
- Trial name
- NCT01226758
- Testing
- Influenza vaccine (FLU-v)
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- PepTcell Limited
Chronic Hepatitis B
A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)
This is a study of sequential therapy with AHB-137 injection followed by TVAX-008 injection in participants living with Chronic Hepatitis B (CHB).
- Trial name
- NCT07897448
- Testing
- AHB-137, TVAX-008
- Volunteers
- 105 people
- Sponsor
- Grand Theravac Life Sciences (Hangzhou) Co., Ltd.
COVID-19
A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children
The purpose of this clinical trial is to learn about the safety and immune responses of the study vaccine (called a bivalent BNT162b2 Omicron containing vaccine) in healthy infants and children.
- Trial name
- NCT05630352
- Testing
- Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
- Volunteers
- healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19 Infection
Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
The purpose of this study is to determine if a CGRP receptor antagonist may potentially blunt the severe inflammatory response at the alveolar level, delaying or reversing the path towards oxygen desaturation, Acute respiratory…
- Trial name
- NCT04346615
- Testing
- Zavegepant (BHV-3500)
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- Pfizer
COVID-19
Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age
The goal of this clinical trial is to evaluate immune response and safety of SARS-CoV-2 subunit protein recombinant vaccine (IndoVac) as a heterologous booster dose in healthy children 12-17 years of age.
- Trial name
- NCT05727215
- Testing
- SARS-CoV-2 subunit protein recombinant vaccine
- Where
- Indonesia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Persistent Infection, Cystic Fibrosis
A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics.
- Trial name
- NCT06159725
- Testing
- CMTX-101
- Where
- 23 sites in United States
- Volunteers
- 43 people
- Sponsor
- Clarametyx Biosciences, Inc.
RSV Infection
A Study of EDP-323 in Healthy Subjects
This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-323 in healthy adult subjects.
- Trial name
- NCT05587478
- Testing
- EDP-323
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Covid19
Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis
The objective of this study will be to evaluate the effect of vaccination on breath VOC content. By capturing and analyzing the breath of anti-COVID-19 vaccinated subjects during the period of antibody production, the…
- Trial name
- COVID-19 (NCT04842708)
- Testing
- vaccination against COVID19
- Where
- Israel
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Scentech Medical Technologies Ltd
Influenza
Study of the Safety and Immunogenicity of NasoVAX Extension
This study is an extension to Study ALT-103-201, a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age.
- Trial name
- NCT03760549
- Testing
- Subjects were administered NasoVAX high dose
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Covid19
LLLT Treatment of Lung Inflammation in COVID-19
To determine if a reduction of pneumonic inflammation occurs after treatment with Low-Level Laser Therapy (LLLT) applying red-light technology in the respiratory system of COVID-19 patients suffering from acute viral pneumonia.
- Trial name
- NCT04524715
- Testing
- Non-invasive red LLLT treatment to chest of patient.
- Where
- United States
- Sponsor
- Ward Photonics LLC
COVID-19
A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects
Primary Objective is to evaluate the safety and efficacy of OT-101+Artemisinin when used in combination with standard of care (SoC) in hospitalized COVID 19 subjects versus SoC+ Artemisinin+Placebo.
- Trial name
- NCT04801017
- Testing
- OT-101, Artemisinin
- Where
- Brazil
- Volunteers
- 18 people
- Sponsor
- Oncotelic Inc.
Influenza
Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination
Immunogenicity and safety of a cell-derived influenza vaccine in adults aged >= 18 and <= 64 years, plus revaccination
- Trial name
- NCT00889889
- Testing
- Cell-Derived Trivalent Subunit Influenza Vaccine
- Where
- 15 sites in United States
- Volunteers
- 1,270 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
URTI, Common Cold
A Novel Cold and Flu Herbal Blend for Reducing the Duration and Severity of the Common Cold
The aim of this study is to evaluate the efficacy of a Novel Herbal Cold \& Flu Blend in reducing the duration of symptoms of the common cold.
- Trial name
- NOURTI (NCT07642648)
- Testing
- Novel Herbal Cold & Flu Blend
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- RDC Clinical Pty Ltd
Allergic Rhinitis
Efficacy and Tolerability of a Topical Microemulsion in Patients With Allergic Rhinitis Due to Sensitization to Pollen
Study design: Randomized, controlled, double-blind, parallel, multicentre multinational clinical trial, to show superiority of an active therapy as compared to a control therapy on intermittent or persistent Allergic Rhinitis.
- Trial name
- NCT01478425
- Testing
- Lipidic Microemulsion, Saline
- Where
- 9 sites in Spain, Sweden
- Volunteers
- 110 people
- Sponsor
- Reig Jofre Group
COVID-19
Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19
This will be a phase 1a randomized, open label, multi-center study with approximately 24 subjects. All subjects will receive standard of care (SOC) per institutional guidelines for treatment of hospitalized patients with COVID-19…
- Trial name
- CRISIS (NCT04425252)
- Testing
- Brequinar, Standard of Care
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Clear Creek Bio, Inc.
COVID-19 (Healthy Volunteers)
Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older
The primary objectives of the study were: To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each study intervention group.
- Trial name
- NCT04537208
- Testing
- CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose)
- Where
- 11 sites in United States
- Volunteers
- 441 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains
The study is to assess whether the virosomal influenza vaccine for season 2012/2013 fulfills the EMA requirements for re-registration of influenza vaccines.
- Trial name
- NCT01631071
- Testing
- Virosomal influenza vaccine
- Where
- Switzerland
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza Immunization, Health Volunteers
A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire
This study aims to assess patient-reported experiences following trivalent recombinant influenza vaccine (RIV3) vaccination using the Vaccinees' Perception of Injection (VAPI) questionnaire, identify factors related to vaccine…
- Trial name
- NCT06765187
- Testing
- Trivalent Recombinant Influenza Vaccine
- Where
- United States
- Volunteers
- 1,007 people, healthy volunteers welcome
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.